Brief: Antengene Corp Says A Member Of Group Has Entered Into An Exclusive, Worldwide License Agreement With Calithera Biosciences
17/05/2021 16:19
May 17 (Reuters) - Antengene Corporation Ltd 6996.HK :
* A MEMBER OF GROUP HAS ENTERED INTO AN EXCLUSIVE, WORLDWIDE
LICENSE AGREEMENT WITH CALITHERA BIOSCIENCES
* AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF CB- 708
(ATG-037), CALITHERA'S SMALL MOLECULE INHIBITOR OF CD73
Source text for Eikon: ID:nHKS4sjQKK
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106